Neumora Therapeutics Launches with $400M Series A Round and Amgen Partnership

Neumora Theapeutics, Inc. (integrating data science and neuroscience to discover precision medicines for brain diseases) launched and raised $400M through its Series A round. The financing was led by Arch Venture Partners, with participation from Alexandria Venture Investments, Altitude Life Science Ventures, Catalio Capital Management, F-Prime Capital, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, re.Mind Capital (Apeiron), Softbank Vision Fund 2, Surveyor Capital (a Citadel company), Waycross Ventures (Byers Capital), and other undisclosed investors. Concurrent with the Series A, Neumora also announced a partnership with Amgen through which the companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities. In addition, Neumora has received a $100M equity investment from Amgen and acquired exclusive global rights to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.